KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Dec 2016 value amounting to $33.3 billion.

  • Teva Pharmaceutical Industries' Cash & Equivalents fell 33.62% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 33.62%. This contributed to the annual value of $3.3 billion for FY2024, which is 2.29% up from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Cash & Equivalents is $2.2 billion, which was up 1.94% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Cash & Equivalents registered a high of $3.3 billion during Q3 2024, and its lowest value of $1.7 billion during Q1 2025.
  • Its 3-year average for Cash & Equivalents is $2.6 billion, with a median of $2.3 billion in 2024.
  • Within the past 5 years, the most significant YoY rise in Teva Pharmaceutical Industries' Revenue - Interest and Investment Income was 27.69% (2015), while the steepest drop was 1.44% (2015).
  • Teva Pharmaceutical Industries' Revenue - Interest and Investment Income (Quarterly) stood at $22.8 billion in 2012, then declined by 0.89% to $22.6 billion in 2013, then grew by 3.31% to $23.3 billion in 2014, then rose by 27.69% to $29.8 billion in 2015, then climbed by 11.99% to $33.3 billion in 2016.
  • Its last three reported values are $2.2 billion in Q3 2025, $2.2 billion for Q2 2025, and $1.7 billion during Q1 2025.